Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

Siemens’ healthcare unit to become standalone business

German technology firm plans to publicly list it as Siemens Healthineers

- PMLiVE

Behavioural science in 2030

A psychological perspective on the future role of personalised medicine

Glyconics appoints CEO

Dr Kam Pooni joins the UK diagnostics firm

- PMLiVE

Pfizer to shut down two UK manufacturing sites

Over 370 jobs at the north London and Hampshire plants are at risk

EU flag

Pfizer’s first-in-class breast cancer therapy wins EU licence

Ibrance given the green light as a first-line treatment in Europe

Are we harnessing the full emotional power of brand creativity?

Creative Director Damien Parsonage breaks down the common misconception that pharma and healthcare marketing for healthcare professionals ought to be entirely scientific and rational. Brands are powerful; here's how to...

Blue Latitude Health

Artificial intelligence firm licenses Janssen candidates for development

UK-based BenevolentAI aims to move them into late-stage trials by mid-2017

Pegasus scoops five ‘Consultancy’ wins, making 2016 a stellar year for the health comms consultancy

Pegasus, an Ashfield company, part of UDG Healthcare plc, last night scooped its fifth ‘consultancy’ award of the year at the PRCA Awards in London’s Park Lane where it secured...

Inizio

National Institute for Health and Care Excellence NICE logo

NICE backs Novartis’ Afinitor and Pfizer’s Xalkori

Provisionally approves breast and lung cancer drugs after greater discounts offered

- PMLiVE

Former Roche CEO and chairman joins Arix Bioscience

Dr Franz Humer becomes a senior independent director

Rethinking pharma communications

Guide: How do you adjust your communications to the new multichannel and multi-stakeholder environment?

Anthill Agency

Bristol-Myers Squibb (BMS) building

BMS teams up with Infinity Pharmaceuticals for Opdivo study

Will test dual therapy potential in targeting tumour resistance to checkpoint inhibitors

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links